Duet Diaphragm
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Multiple
- Barrier
- Vaginal Gel
-
Intended Duration:
- Pericoital
- Development Stage: Phase II
- Developer(s)/researcher(s): ReProtect Inc.
Details
- API: Copper
-
Mechanism of Action:
- Physical Barrier
- Anti-Microbial
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Inactive Materials: Plastic
- Regimen: On Demand
- MPT: Potential MPT
Product Status
Lead development company is inactive, and their technologies do not appear to have been transferred to new development teams.
History
In 2005, ReProtect received NIH funding for further development of Duet device design and manufacturing., Prior research had been conducted on the acceptability of the Duet as a menstrual collection device. Ph III trial results indicated non-inferiority to SRA-approved spermicide + barrier device combination. Development as a combination contraceptive appears to have largely ceased following the conclusion of the trial, though BufferGel alone continued to be evaluated for STI prevention through the early 2010s.